Inspire Medical Systems, Inc. reported a revenue increase of 10.8% for the second quarter of 2025, generating $217.1 million compared to $195.9 million in the same period last year. For the first half of 2025, the company achieved total revenue of $418.4 million, reflecting a 16.3% rise from $359.9 million in the first half of 2024. Despite this growth, Inspire recorded a net loss of $3.6 million for the second quarter, a significant decline from a net income of $9.8 million in the prior year. The company’s gross margin slightly decreased to 84.0% from 84.8% year-over-year, primarily due to increased costs associated with higher sales volume and inventory charges.
In terms of operational metrics, Inspire's U.S. revenue accounted for 95.4% of total sales in the second quarter, with a notable increase of $19.3 million compared to the previous year. International sales also grew, reaching $9.9 million, a 23% increase. The company attributed its revenue growth to enhanced market penetration and increased awareness of its Inspire system, although it faced challenges such as ENT surgeon capacity constraints and delays in therapy adoption as patients awaited the launch of the new Inspire V system.
Inspire has made strategic investments in its product development, including the full launch of the Inspire V system in May 2025, which is expected to drive future growth. The company has also expanded its sales force, increasing the number of U.S. sales territories to 348 and field clinical representatives to 259 as of June 30, 2025. However, the company anticipates that some customers may delay purchasing the new system while utilizing existing inventory of the previous model, which could impact revenue in the near term.
Financially, Inspire's cash and cash equivalents decreased to $106.9 million as of June 30, 2025, down from $150.2 million at the end of 2024. The company reported a working capital of $479.8 million, reflecting a decrease primarily due to share repurchases and inventory purchases. Inspire's total liabilities increased to $124.4 million, up from $118.7 million at the end of 2024, while stockholders' equity stood at $677.8 million.
Looking ahead, Inspire Medical Systems remains focused on expanding its market presence and enhancing its product offerings. The company plans to continue investing in research and development to support future generations of its Inspire systems and to navigate the evolving healthcare landscape, including potential impacts from new weight-loss medications that may affect demand for its products. Despite the challenges, Inspire is optimistic about its growth trajectory and the continued adoption of its innovative solutions for obstructive sleep apnea.
About Inspire Medical Systems, Inc.
Inspire Medical Systems develops and commercializes minimally invasive neurostimulation devices for obstructive sleep apnea (OSA). Its proprietary Inspire system uses closed-loop hypoglossal nerve stimulation to maintain airway openness, offering a safe, effective alternative to CPAP. The company targets sleep centers and ENT physicians globally, emphasizing clinical data, patient compliance, and reimbursement strategies to expand access and improve patient outcomes.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.